We recruited 17 BCR::ABL1-positive MPAL patients; 15 received TKI combined with induction chemotherapy: 8 with imatinib, 4 with dasatinib, 2 with orebatinib, and 1 with flumatinib. The gene discussed is ABL1; the disease is mixed phenotype acute leukemia.